The wolverine stack peptide is BPC-157 and TB-500 sold together, either premixed in one vial or as separate vials. BPC-157 is a 15-residue peptide of 1,419.5 g/mol. TB-500, in the HHS policy published on 30 October 2026, is the 7-residue fragment Ac-LKKTETQ, though some sources use the name for full-length thymosin beta-4.
Renovita Research supplies the pairing as the BPC-157/TB-500 Blend 20mg (10/10) (RESEARCH USE ONLY), one lyophilized vial labeled as 10 mg of each peptide, and in three multi-vial kits. The supplier specifies the TB-500 in that vial as full-length thymosin beta-4. This guide, updated 17 November 2026, shows how a lab can tell which TB-500 a vial holds, what a 1:1 label means once mass is turned into molecules, where the two compounds stand with the FDA, HHS and WADA today, and how to read the blend’s certificate line by line.
Key Takeaways
- The wolverine stack is BPC-157 plus TB-500. Healthy Male calls the name a marketing term, and the name sets no ratio or form.
- BPC-157 is the synthetic 15-residue peptide GEPPPGKPADDAGLV, a partial sequence of a protein first isolated from human gastric juice.
- “TB-500” names two different molecules. The FDA and HHS define it as the acetylated 7-residue fragment Ac-LKKTETQ. Healthy Male describes it as a synthetic version of the 43-residue thymosin beta-4 protein. The mass on a certificate tells them apart: about 889 Da against about 4,960 Da.
- A blend labeled 10 mg and 10 mg is 1:1 by mass only. In molecules, the ratio is about 1 BPC-157 to 1.6 TB-500 if the vial holds the fragment, or about 3.5 BPC-157 to 1 TB-500 if it holds the full protein. The TB-500 in Renovita’s blend vial is full-length thymosin beta-4 by its supplier’s specification, so the 3.5 to 1 case applies to it.
- Neither compound is an FDA-approved drug. Both sat in the FDA’s category 2 from September 2023 until 22 April 2026, and both appear in a draft HHS compounding policy filed on 28 October 2026. WADA prohibits both in sport.
What is in the wolverine stack?
The wolverine stack is two peptides. Healthy Male, a men’s health organization funded by the Australian Government Department of Health, Disability and Ageing, says the name borrows the X-Men character and calls it “a marketing term, not a scientific one”. Because the name sets no ratio, format or form, two vials sold as “wolverine” can differ in ratio, in format and in which TB-500 they hold.
| Component | What it is | Length | Molecular weight | Source |
|---|---|---|---|---|
| BPC-157 | Synthetic partial sequence of body protection compound | 15 residues | 1,419.5 g/mol | PubChem CID 9941957 |
| TB-500 (fragment) | Acetylated residues 17 to 23 of thymosin beta-4, Ac-LKKTETQ | 7 residues | 949.1 g/mol as the acetate salt | HHS policy, Appendix B |
| Thymosin beta-4 (full length) | Actin-binding protein | 43 residues after the starting methionine is removed | about 4,960 g/mol (worked below) | UniProt P62328 |
What is BPC-157?
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, the formula C62H98N16O22 and a molecular weight of 1,419.5 g/mol (PubChem CID 9941957). The US Anti-Doping Agency describes it as a partial sequence of the body protection compound (BPC) originally isolated from human gastric juice, and cites the 1993 paper by Sikiric and colleagues, “A new gastric juice peptide, BPC”. USADA adds that the BPC-157 sold today is all synthetic, made to match that human sequence.
One detail matters on a certificate. HHS gives the acetate salt of BPC-157 a weight of “1419.54 + x(60.05) g/mol”, where x stands for a variable number of acetate counter-ions. Acetate adds weight to the powder without adding peptide, so the weight of powder in a vial and the weight of peptide in it are two different figures.
Renovita sells BPC-157 alone as the BPC-157 – 10mg (RESEARCH USE ONLY) vial, whose page describes it as derived from a gastric protein sequence and characterized by stability in acidic conditions.
What is TB-500, and which molecule is it?
TB-500 is a name that FDA and HHS apply to a 7-residue fragment and Healthy Male applies to the whole protein. The parent protein, thymosin beta-4, has 43 amino acids once its starting methionine is removed, carries an acetyl group on its first serine, and binds and sequesters actin monomers (UniProt P62328).
In 2012 the Doping Control Laboratory at Ghent University analyzed a product sold as TB-500 and found Ac-LKKTETQ, the N-terminally acetylated 17 to 23 fragment of thymosin beta-4, by liquid chromatography with high-resolution mass spectrometry (Esposito et al., Drug Testing and Analysis, 2012). Four named sources use the name today:
- FDA: its compounding safety page lists “Thymosin beta-4, fragment (LKKTETQ), also known as TB-500”.
- HHS: the October 2026 policy gives TB-500 acetate the sequence Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln-OH and a weight of 949.1 g/mol (Appendix B).
- Healthy Male: describes TB-500 as “a synthetic version of thymosin beta-4”, naming the whole protein and giving no length.
- Renovita’s own Tri Blend page: describes its TB-500 vials as a “Synthetic analog of Thymosin Beta-4”, which does not say which form.
How the mass tells the two apart
Mass spectrometry settles the question in one figure. The fragment’s free base is about 889 Da: the HHS acetate weight of 949.1 g/mol less one acetate of 60.05. Full-length acetylated thymosin beta-4 is about 4,960 Da, worked from UniProt’s 5,053 Da for the 44-residue precursor, less the starting methionine (about 131 Da), plus the acetyl group (about 42 Da). The calculated masses differ by more than fivefold, so a certificate that prints the observed mass answers the question. A certificate that prints only the name does not.
What does 1:1 by mass mean in a BPC-157/TB-500 blend?
A blend labeled 10 mg of BPC-157 and 10 mg of TB-500 holds equal weights, and equal weights of different-sized molecules are unequal numbers of molecules. Dividing 10 mg by each molecular weight gives the count in micromoles (µmol):
| 10 mg of | Molecular weight used | Amount | Molecules per molecule of BPC-157 |
|---|---|---|---|
| BPC-157 | 1,419.5 g/mol (PubChem) | 7.0 µmol | 1 |
| TB-500 as Ac-LKKTETQ | about 889 g/mol (HHS, free base) | 11.2 µmol | about 1.6 |
| TB-500 as full-length thymosin beta-4 | about 4,960 g/mol (worked from UniProt) | 2.0 µmol | about 0.29 |
So the same “10/10” label means about 1 molecule of BPC-157 to 1.6 of TB-500 if the vial holds the fragment, or about 3.5 molecules of BPC-157 to 1 of TB-500 if it holds the whole protein. Between the two forms, the molecule ratio differs about 5.6-fold, which matters to any lab comparing results across suppliers or across its own batches. These calculations assume 10 mg of each peptide excluding counter-ions. Calculations based on salt or powder mass also require the acetate content.
What evidence supports the BPC-157 and TB-500 pairing?
Sellers pair BPC-157 and TB-500 because the research each name points to is tissue-repair research, and the combination is claimed to speed healing and reduce inflammation, as Healthy Male reports. That is the proposed rationale. The evidence for it is narrower.
Healthy Male describes cell and animal research on BPC-157 and thymosin beta-4; it says TB-500 is assumed to behave similarly to the parent protein rather than being independently validated. It reports that the BPC-157 rodent and cell results, on tissues such as tendons, joints, nerves, the gut and skin, “haven’t been supported by studies in humans”. The same source states “There is no evidence of benefits from either peptide in isolation, or together.”
Data on full-length thymosin beta-4 does not carry over to a 7-residue fragment by default, so a study design that cites the protein’s literature needs to know which molecule is in the vial.
USADA adds that human trial data on BPC-157 is thin because studies “appear to have been cancelled or stopped without any published conclusions”.
Is the wolverine stack FDA approved?
No. USADA states that BPC-157 is “not approved for human clinical use by the U.S. Food and Drug Administration (FDA) or any other global health authority”, and no premixed blend is an approved product either. Three primary records show where things stand on 17 November 2026:
- FDA category 2, 2023 to 2026. HHS records that BPC-157 was in the FDA’s category 2 (bulk substances that may present significant safety risks in compounding) “from September 2023 until April 22, 2026”, and TB-500 “from September 29, 2023, until April 22, 2026” (HHS Appendix B).
- FDA list today. The FDA page, content current as of 22 April 2026, now shows BPC-157 and the LKKTETQ fragment under “Bulk drug substances nominated but withdrawn”. FDA’s stated concern for both is immunogenicity from aggregation and peptide-related impurities, and for BPC-157 also characterization of the substance (FDA).
- HHS draft policy, October 2026. HHS filed a notice on 28 October 2026, published on 30 October 2026 as Federal Register document 2026-22192, announcing a draft enforcement discretion policy for 503A compounding with six peptides in its Appendix A, BPC-157 and TB-500 among them. The notice cites “the lack of availability of approved products” and says the policy “is not binding on HHS or the public.”
The HHS policy concerns pharmacy compounding. It does not approve either compound as a drug, and it says nothing about research-use supply.
Are BPC-157 and TB-500 banned in sport?
Yes. The WADA 2026 Prohibited List names BPC-157 under S0, non-approved substances, and lists “Thymosin-β4 and its derivatives e.g. TB-500” under S2, peptide hormones, growth factors, related substances and mimetics. The Ghent paper above also proposed a method to detect the Ac-LKKTETQ fragment in plasma and urine (Esposito et al., 2012).
Blend vial or separate vials: what is the difference for a lab?
A blend vial fixes the ratio at 10 mg to 10 mg. Separate vials let a lab set its own ratio, run each compound alone as a control, or open one compound without the other. Renovita carries BPC-157 and TB-500 together in four products. Contents below are as the product pages list them; the totals are simple multiplication:
| Product (RESEARCH USE ONLY) | Vials | BPC-157 total | TB-500 total | Other peptides |
|---|---|---|---|---|
| BPC-157/TB-500 Blend 20mg (10/10) | 1 vial, premixed | 10 mg | 10 mg | none |
| Dual Peptide Reference Kit (RESEARCH USE ONLY) | 3 BPC-157 (10 mg) + 2 TB-500 (10 mg) | 30 mg | 20 mg | none |
| Tri Blend: Multi-Peptide Reference Kit | 3 BPC-157 (10 mg) + 2 TB-500 (10 mg) + 1 GHK-Cu (100 mg) | 30 mg | 20 mg | 100 mg GHK-Cu |
| Quad Blend: Multi-Peptide Reference Kit | 3 BPC-157 (10 mg) + 2 TB-500 (10 mg) + 1 GHK-Cu (100 mg) + 2 KPV (10 mg) | 30 mg | 20 mg | 100 mg GHK-Cu, 20 mg KPV |
For labs that want the two compounds apart, the Dual Peptide Reference Kit (RESEARCH USE ONLY) supplies them as five single vials, and the TB-500 – 10mg (RESEARCH USE ONLY) vial is sold on its own.
Renovita’s research-grade peptides are sold strictly for laboratory and research use only, not for human or animal consumption. We ship all of these only to addresses within the United States.
How should a blend’s certificate of analysis be read?
A two-peptide vial needs more from its certificate of analysis (COA) than a single peptide does, because one purity figure can hide two components. HHS’s October 2026 appendix lists the identity methods it accepts for these peptides, among them HPLC coelution with a reference standard, MS for monoisotopic mass, quantitative amino acid analysis and tandem MS sequencing (HHS Appendix B). For a blend, check for:
- Identity of each peptide, with the method named.
- Which TB-500: an observed mass near 889 Da (fragment) or near 4,960 Da (full length).
- Purity by HPLC, with the method, and whether the figure covers each component or the blend as an average.
- A measured amount for each component, set against its label.
- A batch number that matches the vial, plus the test date.
Reading the certificate for batch STL2607WV20
The blend’s product page lists purity as ≥ 99% (HPLC) and storage at −20 °C or below, and links the certificate for batch STL2607WV20, certified on 2 July 2026. Set against the checklist:
| Check | What the certificate reports | Reading |
|---|---|---|
| Identity | “BPC-157/TB-500” by LC-MS | Both named; no observed masses printed |
| Which TB-500 | No observed mass printed | Full-length thymosin beta-4 per the supplier’s specification; the certificate itself does not show the form |
| Purity | 99.481% blend average, RP-HPLC, C18 column, DAD at 214 nm | One figure for the vial as a whole, no per-component purity |
| Amount per component | Net content reported for BPC-157 and for TB-500, each against 10 mg labeled | A separate amount for each component, as the checklist asks |
| Batch and date | STL2607WV20, 2 July 2026 | Matches the product page link |
The supplier’s specification answers the fragment-or-protein question from earlier: the TB-500 in this blend is full-length thymosin beta-4, the 43-residue protein. The certificate does not show this, because its TB-500 line carries a name with no observed mass. A lab that wants the test result to show the form can ask for the observed mass of the TB-500 peak, which the LC-MS run behind the identity line will have produced. For full-length thymosin beta-4, that mass is about 4,960 Da.
Frequently Asked Questions
Is the wolverine peptide one peptide or two?
It is two. “Wolverine peptide” and “wolverine stack” both name BPC-157 paired with TB-500, sold either premixed in one vial or as separate vials.
What is in a wolverine blend vial?
Renovita’s blend vial is labeled as 20 mg of lyophilized powder: 10 mg of BPC-157 and 10 mg of TB-500. Its supplier specifies the TB-500 as full-length thymosin beta-4. The certificate for batch STL2607WV20 reports a measured net content for each of the two.
Is TB-500 the same as thymosin beta-4?
Not always. The FDA and HHS use TB-500 for Ac-LKKTETQ, a 7-residue fragment of the 43-residue thymosin beta-4 protein. Healthy Male uses it for a synthetic version of the full protein. The observed mass on a certificate shows which one a vial holds.
Are BPC-157 and TB-500 banned in sport?
Yes. The WADA 2026 Prohibited List covers BPC-157 under S0 and thymosin beta-4 derivatives, including TB-500, under S2.
How is a lyophilized BPC-157/TB-500 blend stored?
The product page lists storage at −20 °C or below.
Where to find the BPC-157/TB-500 blend
Full specifications and the batch certificate are on the BPC-157/TB-500 Blend 20mg (10/10) (RESEARCH USE ONLY) page.